Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: A randomized clinical trial

JAMA

Volumn 312, Issue 4, 2014, Pages 362-371

  Mugo, Nelly R ^a,b,c   Hong, Ting ^a   Celum, Connie ^a,d   Donnell, Deborah ^a,e   Bukusi, Elizabeth A ^a,b,d   John Stewart, Grace ^a,d   Wangisi, Jonathan ^f   Were, Edwin ^g   Heffron, Renee ^a   Matthews, Lynn T ^h   Morrison, Susan ^a   Ngure, Kenneth ⁱ   Baeten, Jared M ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c KENYATTA NATIONAL HOSPITAL   (Kenya)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f THE AIDS SUPPORT ORGANIZATION   (Uganda)

^g MOI UNIVERSITY   (Kenya)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; TENOFOVIR DISOPROXIL;

ACUTE DIARRHEA; ADULT; ARTICLE; BRONCHOPNEUMONIA; CHILD DEATH; CHILD GROWTH; CONCEPTION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT MORTALITY; INFECTION PREVENTION; KIDNEY FUNCTION; LIVE BIRTH; MALARIA; NEWBORN SEPSIS; OUTCOME ASSESSMENT; PERINATAL ASPHYXIA; PERINATAL DEATH; PHASE 3 CLINICAL TRIAL; PREEXPOSURE PROPHYLAXIS; PREGNANCY OUTCOME; PREGNANCY TEST; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ADENINE; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CHILD DEVELOPMENT; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FAMILY CHARACTERISTICS; FEMALE; FERTILIZATION; HETEROSEXUALITY; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; KENYA; MALE; ORGANOPHOSPHONATES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PRENATAL CARE; UGANDA;

EID: 84904574624     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.8735     Document Type: Article

References (38)

1. Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
2. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
3. Choopanya K, Martin M, Suntharasamai P, et al Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study). Lancet. 2013;381(9883):2083- 2090.
4. Cohen MS, Chen YQ, McCauley M, et al HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
5. Mujugira A, Heffron R, Celum C, et al. Fertility intentions and interest in early antiretroviral therapy among East African HIV-1-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr. 2013;63(1):e33-e35.
6. Antiretroviral Pregnancy Registry. The Antiretroviral Pregnancy Registry interim report. http://www.apregistry.com/forms/interim-report.pdf. Accessed January 25, 2014.
7. Stellbrink HJ, Orkin C, Arribas JR, et al ASSERT Study Group. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963-972.
8. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51(8):937-946.
9. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.
10. Ransom CE, Huo Y, Patel K, et al; P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr. 2013;64(4):374-381.
11. Gibb DM, Kizito H, Russell EC, et al DART Trial Team. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9(5):e1001217.
12. Siberry GK, Williams PL, Mendez H, et al Pediatric HIV/AIDS Cohort Study (PHACS). Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26(9):1151-1159.
13. Mujugira A, Baeten JM, Donnell D, et al; Partners PrEP Study Team. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One. 2011;6(10):e25828.
14. Murnane PM, Celum C, Mugo N, et al; Partners PrEP Study Team. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals. AIDS. 2013;27(13):2155-2160.
15. Ndase P, Celum C, Campbell J, et al. Successful discontinuation of the placebo arm and provision of an effective HIV prevention product after a positive interim efficacy result: the Partners PrEP Study experience. J Acquir Immune Defic Syndr. 2014;66 (2):206-212.
16. Joint United National Programme on HIV/AIDS (UNAIDS). Good Participatory Practice: Guidelines for Biomedical HIV Prevention Trials 2011. Geneva, Switzerland: UNAIDS; 2011.
17. UNAIDS/WHO. Ethical Considerations in Biomedical HIV Prevention Trials. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2007.
18. Matthews LT, Heffron R, Mugo NR, et al. High medication adherence during periconception periods among HIV-1-uninfected women in a clinical trial of antiretroviral pre-exposure prophylaxis. J Acquir Immune Defic Syndr. http://journals.lww.com/jaids/Abstract/publishahead/High-medication-adherence- during-periconception.97879.aspx.
19. The WHO child growth standards, 2006. http://www.who.int/childgrowth/en/. Accessed January 25, 2014.
20. Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format. BMC Pediatr. 2003;3(13):13.
21. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013;57(12):1773-1781.
22. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, Switzerland:World Health Organization; 2013.
23. HHS Panel on Treatment of HIV-Infected PregnantWomen and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/ contentfiles/lvguidelines/PerinatalGL.pdf. Accessed January 26, 2014.
24. Pan CQ, Mi LJ, Bunchorntavakul C, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci. 2012;57(9):2423-2429.
25. Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm312210.htm. Updated July 17, 2012. Accessed January 25, 2014.
26. Wilcox AJ, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med. 1988;319(4):189-194.
27. Ngure K, Heffron R, Mugo NR, et al Partners in Prevention HSVHIV Transmission Study Team. Contraceptivemethod and pregnancy incidence among women in HIV-1-serodiscordant partnerships. AIDS. 2012;26(4):513-518.
28. Odutola A, Baisley K, Hayes RJ, et al. Pregnancy and contraceptive use among women participating in an HIV prevention trial in Tanzania. Sex Transm Infect. 2012;88(6):436-443.
29. Reid SE, Dai JY, Wang J, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr. 2010;53(5):606-613.
30. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977-1987.
31. Ngure K, Mugo N, Celum C, et al. A qualitative study of barriers to consistent condom use among HIV-1 serodiscordant couples in Kenya. AIDS Care. 2012;24(4):509-516.
32. Cherutich P, Kaiser R, Galbraith J, et al KAIS Study Group. Lack of knowledge of HIV status a major barrier to HIV prevention, care and treatment efforts in Kenya. PLoS One. 2012;7(5):e36797.
33. Beyeza-Kashesya J, Kaharuza F, Mirembe F, et al. The dilemma of safe sex and having children: challenges facing HIV sero-discordant couples in Uganda. Afr Health Sci. 2009;9(1):2-12.
34. Beyeza-Kashesya J, Ekstrom AM, Kaharuza F, et al. My partner wants a child: a cross-sectional study of the determinants of the desire for children among mutually disclosed sero-discordant couples receiving care in Uganda. BMC Public Health. 2010;10(247):247.
35. Kakaire O, Osinde MO, Kaye DK. Factors that predict fertility desires for people living with HIV infection at a support and treatment centre in Kabale, Uganda. Reprod Health. 2010;7(27):27.
36. Matthews LT, Baeten JM, Celum C, Bangsberg DR. Periconception pre-exposure prophylaxis to prevent HIV transmission. AIDS. 2010;24(13):1975- 1982.
37. Mugo NR, Heffron R, Donnell D, et al Partners in Prevention HSV/HIV Transmission Study Team. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS. 2011;25(15):1887-1895.
38. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States-2014: a clinical practice guideline. 2014.